Stretch Mark Creams & Oils

Pregnancy

ACOG says there is no proof that marketed treatments prevent stretch marks. Its page says a heavy moisturizer may keep skin soft but will not remove marks. The Cochrane page, published in 2022, reports six trials involving 800 women. Five trials with 474 women found no statistically significant average reduction in new marks (RR 0.74, 95% CI 0.53-1.03; I2=65%); the authors found no high-quality evidence for prevention. Its search ended on 31 October 2011. A 2026 systematic review of four randomized trials with 671 pregnant participants reported a coconut-oil benefit, while rose, sesame, and sweet almond oils did not show a benefit. The authors called for larger, higher-quality, blinded trials. The accessible abstract does not report the live entry's 25% versus 45% result. Topical retinoid medicines are a separate ingredient issue. ACOG says absorption is low but use during pregnancy is generally not recommended. EMA says specified topical retinoids are contraindicated during pregnancy as a precaution, while noting negligible systemic absorption and that fetal harm is unlikely. The FDA-approved Retin-A Micro label is for acne; it says human studies have not established a drug-associated risk of major birth defects or miscarriage, but notes limitations in those studies. A 2012 prospective study compared 235 first-trimester-exposed pregnancies with 444 controls. It found no significant difference in spontaneous abortion (OR 1.5, 95% CI 0.8-2.7) or major birth defects (OR 1.8, 95% CI 0.6-5.4). The study also reported a 3-fold higher rate of elective termination (3.4, 95% CI 1.5-7.8), without stating a cause. A 2026 Nordic cohort included 2,172 first-trimester topical-retinoid exposures. Major birth defects occurred in 3.3% of exposed infants and 3.0% of unexposed infants (adjusted RR 1.1, 95% CI 0.87-1.38). The researchers did not observe an increased risk, but included pregnancies ending in birth at 22 weeks or later. A 2026 meta-analysis of eight studies and 3,632,118 pregnancies found no statistically significant association with major birth defects or spontaneous abortion; its authors said the findings were driven mainly by one large registry study. These human studies do not remove the ingredient-specific precaution or establish that every cosmetic product has the same formulation or exposure.

Breastfeeding

ACOG says most stretch marks fade after birth, though some may remain, and that a heavy moisturizer may keep skin soft but will not remove marks. The Cochrane review and the 2026 oil review assess prevention during pregnancy, not products first used after birth while breastfeeding. The AAD advises people who are breastfeeding to check with a doctor before treating stretch marks. No breastfeeding-specific study testing prevention or reduction after birth was identified in the reviewed sources.

What was tested

The Cochrane review compared topical preparations with placebo, no treatment, or other topical products. It measured whether stretch marks developed and their severity. The 2026 oil review included four randomized trials with 671 pregnant participants and summarized the oils tested; its abstract does not provide a pooled effect estimate. The retinoid pregnancy studies examined topical medicine exposure and pregnancy outcomes, not the effectiveness of cosmetic stretch-mark creams. The 2026 treatment review covered existing stretch marks, not pregnancy or breastfeeding safety.